[Form 4] Revolution Medicines, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Revolution Medicines (RVMD) — Form 4 insider activity: President and CEO Mark A. Goldsmith reported option exercises and share sales on 11/07/2025 pursuant to a Rule 10b5-1 trading plan adopted on December 19, 2024. He exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, then sold 30,000 shares at a weighted average price of $60.3102 (trades ranged from $60.00 to $60.88).

On 11/12/2025, he recorded transfers of 50,000 shares to the Jonathan Goldsmith Revocable Trust and 50,000 shares to the Rebecca Goldsmith Revocable Trust, and reported indirect holdings in multiple family trusts. Following the transactions, direct beneficial ownership amounts were updated across entries, and his beneficial holdings include 193,475 restricted stock units.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

GOLDSMITH MARK A

(Last) (First) (Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY CA 94063

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/07/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/07/2025		M(1)		26,479	A	$1.12	374,342(2)(3)	D
Common Stock	11/07/2025		M(1)		3,521	A	$4.09	377,863(2)(3)	D
Common Stock	11/07/2025		S(1)		30,000	D	$60.3102(4)	347,863(2)(3)	D
Common Stock	11/12/2025		G(5)		50,000	D	$0	297,863(2)(3)	D
Common Stock	11/12/2025		G(6)		50,000	D	$0	247,863(2)(3)	D
Common Stock	11/12/2025		G		50,000	A	$0	70,424	I	Trust(7)
Common Stock	11/12/2025		G		50,000	A	$0	54,498(8)	I	Trust(9)
Common Stock								15,926(8)	I	Trust(10)
Common Stock								570,050(2)	I	Trust(11)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$1.12	11/07/2025		M(1)			26,479	03/29/2022	04/19/2028	Common Stock	26,479	$0	0	D
Stock Option (Right to Buy)	$4.09	11/07/2025		M(1)			3,521	03/13/2023	03/12/2029	Common Stock	3,521	$0	177,708	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Mark A. Goldsmith on December 19, 2024.

2. Reflects the transfer of 104,446 shares previously held directly by the Reporting Person into a family trust.

3. Includes 193,475 restricted stock units.

4. This transaction was executed in multiple trades at prices ranging from $60.00 to $60.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. Represents a transfer to the Jonathan Goldsmith Revocable Trust.

6. Represents a transfer to the Rebecca Goldsmith Revocable Trust.

7. Held by Jonathan Goldsmith Revocable Trust.

8. Reflects the transfer of 4,498 shares.

9. Held by Rebecca Goldsmith Revocable Trust.

10. Held by Rebecca Eve Goldsmith Trust under the Goldsmith Children's 2011 Irrevocable Education Trust, dated December 15, 2011.

11. Held by Mark A. Goldsmith and Anne E. Midler 2002 Revocable Living Trust.

Remarks:

President and Chief Executive Officer

	/s/ Jack Anders, as attorney-in fact for Mark A. Goldsmith	11/12/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did RVMD's CEO report on Form 4?

On 11/07/2025, he exercised options for 26,479 shares at $1.12 and 3,521 shares at $4.09, and sold 30,000 shares at a weighted average of $60.3102.

Was the RVMD share sale under a 10b5-1 plan?

Yes. The transactions were made under a Rule 10b5-1 trading plan adopted on December 19, 2024.

What were the sale price details for RVMD shares?

The 30,000 shares were sold at a weighted average price of $60.3102, with individual trades ranging from $60.00 to $60.88.

What trust transfers did the RVMD CEO report?

On 11/12/2025, 50,000 shares were transferred to the Jonathan Goldsmith Revocable Trust and 50,000 to the Rebecca Goldsmith Revocable Trust.

How many restricted stock units are included in reported RVMD holdings?

The reported beneficial ownership includes 193,475 restricted stock units.

What is the reporting person’s role and relationship to RVMD?

He is a Director and the President and Chief Executive Officer of Revolution Medicines, Inc.